Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.55 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.55 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.55 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.55 |
| ▸ | FAP | Q12884 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6877826 | 1.00 | DPP4 (0.55) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL6878871 | 1.00 | DPP4 (0.55) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL14903341 | 1.00 | DPP4 (0.55) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL6880693 | 1.00 | DPP4 (0.55) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL6880548 | 1.00 | DPP4 (0.55) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL14903408 | 1.00 | DPP4 (0.55) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL14903318 | 1.00 | DPP4 (0.55) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL14903327 | 1.00 | DPP4 (0.55) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL15216699 | 0.98 | DPP4 (0.53) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL6878791 | 0.98 | DPP4 (0.53) | DPP4DPP8DPP9DPP7FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10238713-B2 | Cyclic tetrapeptides and therapeutic applications thereof | LODZ UNIVERSITY OF TECHNOLOGY (PL) | 2019-03-26 | — | — | US | disclosed |
| US-20170157204-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | LODZ UNIVERSITY OF TECHNOLOGY (PL) | 2017-06-08 | — | — | US | disclosed |
| US-20170157204-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | LODZ UNIVERSITY OF TECHNOLOGY (PL) | 2017-06-08 | — | — | US | disclosed |
| US-9382292-B2 | Cyclic tetrapeptides and therapeutic applications thereof | PEPTADERM SP. Z O.O. (PL) | 2016-07-05 | — | — | US | disclosed |
| US-9382292-B2 | Cyclic tetrapeptides and therapeutic applications thereof | PEPTADERM SP. Z O.O. (PL) | 2016-07-05 | — | — | US | disclosed |
| US-20130108655-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | PEPTADERM SP. Z O.O. (PL) | 2013-05-02 | — | — | US | disclosed |
| US-20130108655-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | PEPTADERM SP. Z O.O. (PL) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157204-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | PNISR, APLNR, VIP | DPP4 442/4885DPP8 302/4885DPP9 296/4885 |
| US-20130108655-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | PNISR, APLNR, VIP | DPP4 442/4885DPP8 302/4885DPP9 296/4885 |
| US-10238713-B2 | Cyclic tetrapeptides and therapeutic applications thereof | PNISR, APLNR, VIP | DPP4 442/4885DPP8 302/4885DPP9 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.